Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Barcelona, Spain.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [10/09/2019 10:10 PDT] Wuhan General Group (China), Inc. (OTC:WUHN), Down By 100.00% ($0.13) From $0.131 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [10/02/2019 07:30 PDT] WUHN Expected to Trade Down After Bearish Patterns Develop
• [08/21/2019 08:03 PDT] WUHN Expected to Trade Down After Bearish Patterns Develop